Online Exclusive Article

Transplantation and Adherence: Evaluating Tacrolimus Usage in Pediatric Patients With Cancer

Micah A. Skeens

Mary S. Dietrich

Nancy Ryan-Wenger

Mary Jo Gilmer

Shelagh A. Mulvaney

Terrah Foster Akard

adherence, tacrolimus, immunosuppression, HSCT, pediatric stem cell transplantation
CJON 2020, 24(5), E57-E64. DOI: 10.1188/20.CJON.E57-E64

Background: Researchers have estimated that about 50% of pediatric patients with chronic illness adhere to tacrolimus therapy, a medication responsible for preventing critical side effects in patients undergoing hematopoietic stem cell transplantation (HSCT).

Objectives: The purpose of this study was to describe patient adherence to tacrolimus by reviewing documentation from the electronic health record and therapeutic drug levels.

Methods: This retrospective descriptive study examined 357 clinic visits by 57 patients undergoing HSCT. Direct (tacrolimus levels) and indirect (subjective reporting) measures were evaluated.

Findings: The authors found that, in 51% of visits, adherence was not documented. The overall nontherapeutic drug level rate was 60%. Because of the small sample size, nonadherence did not statistically correlate with nontherapeutic levels. The findings highlight the need for adherence awareness, assessment, and documentation in clinical practice.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.